AbbVie has opened a small-molecule manufacturing facility in Singapore as part of a combined $320 million investment to expand small-molecule and biologics manufacturing in Singapore. The facility represents the company’s first manufacturing facility in Asia. 

The facility will support the growth of AbbVie’s oncology and women’s health pipeline and will provide manufacturing capacity for emerging compounds within AbbVie’s oncology and immunology pipeline. The new 120,000-square-meter site, located in the Tuas Biomedical Park, will also include a biologics manufacturing facility that is expected to be fully operational by the end of 2018.

AbbVie first announced the $320 million investment in 2014. Other AbbVie operations in Asia include research and development functions in Tokyo, Japan, and Shanghai, China as well as commercial operations throughout the region.

The new Singapore facility will employ more than 250 new employees, the majority of whom will be hired locally in Singapore, including skilled positions across manufacturing, technical operations, administration, quality, information technology and supply chain.

AbbVie’s manufacturing network now includes 13 locations across the US (including Puerto Rico), Europe, and Asia as well as strategic partnerships with third-party manufacturers.

Source: AbbVie